Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status.

Allyson HartYoon Son AhnCrystal WatsonMelissa SkeansArie BarlevBryn ThompsonVikas R Dharnidharka

Published in: Journal of medical economics (2021)

PTLD represents a considerable HRU and cost burden following kidney transplant, and the burden is most pronounced in patients who die within 6 months.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
risk factors
chronic kidney disease
peritoneal dialysis
epstein barr virus
healthcare
patient reported outcomes
health insurance
affordable care act